查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470476

心臟衰竭治疗市场：按治疗、类型、阶段和最终用户划分 - 全球预测，2024-2030 年

Heart Failure Therapeutics Market by Treatment (Medical Devices, Medicines, Surgery), Type (Diagnosis, Prognosis), Stage, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年心臟衰竭治疗市场规模为239.8亿美元，2024年达261.6亿美元，预计2030年将达481.3亿美元，复合年增长率为10.46%。

由于人口老化越来越容易罹患心臟病，心臟衰竭治疗市场正处于上升轨道。虽然医疗技术的进步改善了心臟衰竭的治疗和管理，但新兴经济体收入水准的提高和健康意识的提高正在导致医疗保健成本增加。在人们渴望优质医疗保健的推动下，对先进治疗的需求持续增长，政府和私人组织正在活性化对研发 (R&D) 的投资。製药和生物技术产业准备推出尖端的製药和生物解决方案，病患监测和分析等数位健康工具准备重新定义医疗保健标准。整个产业正在形成将生物技术新兴企业的创新与成熟製药公司的影响力相结合的策略联盟，而个人化医疗的发展正在为高度个人化的治疗方法打开大门。然而，这个市场面临监管复杂性和报销挑战。与研发和治疗解决方案相关的巨额成本可能会阻碍市场成长。其他障碍包括一些地区对心臟衰竭的诊断不足和认识不足、关键药物专利到期导致学名药竞争，以及患者坚持治疗和生活习惯方面持续存在的问题。为了扩大我们的业务，我们需要专注于创新药物的开发，例如基因疗法和干细胞治疗研究。将人工智慧和机器学习纳入诊断和持续护理，以及改善远端患者监测系统，可以显着减少再入院率并增强门诊护理。此外，联合治疗的研究预计将增加患者的利益，创造具有成本效益的治疗方法，并将市场扩展到低收入者。

主要市场统计
基准年[2023] 239.8亿美元
预测年份 [2024] 261.6亿美元
预测年份 [2030] 481.3亿美元
复合年增长率（%） 10.46%

治疗：消费者广泛转向处方药和个人化药物来管理心臟健康

在心臟衰竭的治疗中，医疗干预措施包括从基于设备的治疗到手术选择。双水平正气压 (BiPAP) 设备可透过提供交替的压力水平来缓解呼吸困难，从而减少心臟的工作负荷。透过手术植入双心室心律调节器可同步心室收缩并增加心抟出量。持续性呼吸道正压通气 (CPAP) 机器始终保持呼吸道畅通，可提高氧饱和度并减轻心臟压力。辅助人工心臟(VAD) 或植入式左心室补助人工心臟(LVAD) 以机械方式支持衰竭的心臟，以确保足够的循环。植入式心臟整流去颤器(ICD) 是一种治疗心律不整的休克疗法。药物方法包括血管收缩素II 受体阻断剂 (ARB) 和各种抗高血压药物，每种药物都能放鬆血管系统并维持血压水平。抗凝血剂和抗血小板药物可降低血栓风险，利尿剂可减少液体储存。硝酸盐用于扩张血管，以减轻心臟负担，他汀类药物则用于降血脂，以预防进一步的心臟併发症。在手术上，心臟再同步治疗（CRT）透过特殊心律调节器优化心室功能，冠状动脉绕道手术手术（CABG）或冠状动脉重组增加心肌灌注。在晚期，心臟瓣膜置换术可以解决瓣膜功能障碍，而当其他治疗失败时，心臟移植是最终的解决方案。

类型：诊断工具和预后创新可以帮助更好地管理心臟健康

心臟衰竭的诊断工具对于及时、准确地识别病理并实现及时、适当的治疗性介入介入至关重要。随着心臟衰竭的流行成为全世界发病和死亡的主要原因，对先进、准确的诊断工具的需求始终很高。用于诊断心臟衰竭的技术包括超音波心臟检查、MRI、CT、血液检查和利尿钠胜肽筛检。心臟衰竭的预后评估对于确定疾病的可能病程、影响治疗决策以及向患者提供预期结果咨询至关重要。预后模型通常包括临床评估、生物标记、基因测试和影像。心臟衰竭诊断和预后市场包括来自信誉良好的提供者的各种工具和服务，旨在改善心臟衰竭患者的预后。该领域最近的创新，特别是利用人工智慧和机器学习的创新，显示了一种更个人化和精确的护理方法的趋势。

区域洞察

心臟衰竭是美国老年人住院的主要原因，这推动了高度重视创新的市场对先进治疗方法的需求。消费者被具有强有力的安全性和功效证据的品牌所吸引，最近的专利强调了创新的配方和传输机制。研究越来越关注尖端基因和干细胞疗法，数位健康和​​个人化医疗的重大投资强化了这一趋势。像「百万爱心」这样的计划对于预防心血管事件至关重要。加拿大拥有对医疗保健系统的支持，该系统表现出对心臟衰竭及其风险的高度认识，并促进广泛获得治疗。市场对突破性治疗方法持开放态度，包括家庭监测技术，以及利用再生医学投资来寻求未来的解决方案。欧洲各地的心臟衰竭治疗受益于反映该地区不同的治疗和报销系统的多样化实践。人口老化和心臟病的流行正在推动对有效治疗方法的需求，欧洲心臟网路倡议旨在透过政策和资金减轻心血管系统的负担。亚太地区对心臟衰竭治疗的需求正在发生显着变化。在政府医疗改革以及本地研究和专利申请增加的推动下，中国的医疗保健产业正在迅速发展，以应对不断变化的人口结构和生活方式的变化。日本以再生医学为中心的先进医学研究正在应对超级老化社会，消费者更青睐国内的医疗创新。印度不断增长的中等收入人口正在为心臟衰竭治疗市场的扩张做出贡献，这得益于旨在改善医疗服务和降低医疗成本的国家医疗保健措施。在中东和非洲，心臟衰竭治疗的情况非常不同。在阿联酋和沙乌地阿拉伯等富裕的中东国家，医疗投资的增加导致尖端治疗方法的增加。然而，透过非洲心臟网络等组织的努力以及鼓励当地製造业和公私合作社的策略，非洲市场正面临着进入和负担能力的挑战。

FPNV定位矩阵

FPNV定位矩阵对于评估心臟衰竭治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对心臟衰竭治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该细分市场竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，以获得市场竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动以及突破性产品开发的见解。

本报告解决了以下关键问题：

1.心臟衰竭治疗市场的市场规模与预测是多少？

2.在心臟衰竭治疗市场的预测期内，我们应该考虑投资哪些产品和应用？

3.心臟衰竭治疗市场的技术趋势和法规结构是什么？

4.心臟衰竭治疗市场主要厂商的市场占有率是多少？

5.进入心臟衰竭治疗市场的合适形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年族群心血管疾病盛行率上升
      • 生活方式的改变增加了心臟衰竭和心律不整的敏感性
      • 心臟衰竭早期诊断和治疗的可用性和偏好
    • 抑制因素
      • 与心臟衰竭治疗相关的高成本和报销问题
    • 机会
      • 心臟衰竭治疗的创新与发展
      • 政府的持续努力和私部门投资的增加
    • 任务
      • 对心臟衰竭病症管理的担忧
  • 市场区隔分析
    • 治疗：消费者转向处方药和个人化药物来管理心臟健康
    • 类型：诊断工具和预后创新可以帮助更好地管理心臟健康
  • 市场趋势分析
  • 俄罗斯和乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章心臟衰竭治疗市场：依治疗分类

  • 介绍
  • 医疗设备
  • 服药
  • 外科手术

第七章心臟衰竭治疗市场：依类型

  • 介绍
  • 诊断
  • 预后

第八章心臟衰竭治疗市场：依阶段

  • 介绍
  • A阶段
  • B阶段
  • C阶段
  • D阶段

第九章心臟衰竭治疗市场：依最终用户分类

  • 介绍
  • 诊所
  • 医院
  • 医学研究所

第10章美洲心臟衰竭治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太心臟衰竭治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲心臟衰竭治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-430D42AA0D2E

[191 Pages Report] The Heart Failure Therapeutics Market size was estimated at USD 23.98 billion in 2023 and expected to reach USD 26.16 billion in 2024, at a CAGR 10.46% to reach USD 48.13 billion by 2030.

The heart failure therapeutics market is observing an upward trajectory, spurred by an aging population that is increasingly susceptible to cardiac conditions. Advances in medical technology are enhancing treatment and management of heart failure, while rising income levels and health awareness in developing economies are leading to greater healthcare expenditure. The demand for sophisticated treatments continues to climb, driven by a population eager for high-quality care, prompting governments and private entities to boost investment in research and development (R&D). Amidst these growth factors lie considerable opportunities; the pharmaceutical and biotech industries are poised to unveil cutting-edge drugs and biological solutions, with digital health tools, such as patient monitoring and analytics, poised to redefine care standards. Strategic alliances are forming across the sector, combining the innovation of biotech start-ups with the reach of established pharmaceutical companies, and the movement towards personalized medicine opens doors to highly individualized therapies. However, this market faces regulatory complexities and reimbursement challenges. The steep costs associated with R&D and therapeutic solutions can hinder market growth. Further obstructions include the underdiagnosis and unawareness of heart failure in some regions, the expiration of key drug patents leading to generic competition, and the ongoing issue of patient adherence to treatment and lifestyle regimes. For business expansion, the industry must zero in on revolutionary drug development, including gene and stem cell therapy research. Incorporating artificial intelligence and machine learning into diagnostics and ongoing care, and improving remote patient monitoring systems could drastically cut hospital readmissions and bolster outpatient care. Research into combination therapies may yield enhanced benefits for patients, while also creating cost-effective treatments that will extend the market's reach into low-income regions.

KEY MARKET STATISTICS
Base Year [2023] USD 23.98 billion
Estimated Year [2024] USD 26.16 billion
Forecast Year [2030] USD 48.13 billion
CAGR (%) 10.46%

Treatment: Extensive consumers shift toward prescribed and personalized medicines for heart health management

In managing heart failure, medical intervention ranges from device-based therapies to surgical options. Bi-level Positive Air Pressure (BiPAP) devices ease the respiratory effort by providing alternating levels of pressure, thereby reducing cardiac workload. Biventricular pacemakers, surgically implanted, synchronize ventricular contractions, enhancing cardiac output. Continuous Positive Airway Pressure (CPAP) devices consistently support open airways, which improves oxygen saturation and eases strain on the heart. Ventricular assist devices (VADs), or heart pumps, and Implantable Left Ventricular Assist Devices (LVADs) offer mechanical support to compromised hearts, ensuring adequate circulation. Implantable Cardioverter-Defibrillators (ICDs) safeguard against arrhythmic events with corrective shocks. Pharmaceutical approaches include Angiotensin II Receptor Blockers (ARBs) and various blood pressure medications that relax vasculature and maintain pressure levels, respectively. Anticoagulants and antiplatelet medications reduce thrombotic risks, whereas diuretics mitigate fluid retention. Nitrates are prescribed for vascular dilation to decrease cardiac load, and statins are utilized for their lipid-lowering effects, preventing further cardiac complications. Surgically, Cardiac Resynchronization Therapy (CRT) optimizes ventricular function through a specialized pacemaker, while Coronary Artery Bypass Grafting (CABG) and Coronary Revascularization procedures enhance myocardial perfusion. In advanced stages, heart valve replacement surgery addresses valvular dysfunction, and heart transplant remains the definitive solution when other interventions fail.

Type: Innovations in the diagnostic tools and prognosis helps in better managing the heart health condition

Diagnostic tools for heart failure are crucial for timely and accurate identification of the condition, thus enabling prompt and appropriate therapeutic interventions. The need for advanced and precise diagnostic tools is consistently high, driven by the prevalence of heart failure as a leading cause of morbidity and mortality worldwide. Technologies utilized in the diagnosis of heart failure include echocardiography, magnetic resonance imaging (MRI), computed tomography (CT), blood tests, and natriuretic peptide screening. Prognostic evaluation in heart failure is essential for determining the likely course of the disease, influencing treatment decisions, and counseling patients regarding expected outcomes. Prognostic models often include clinical assessment, biomarkers, genetic testing, and imaging modalities. The market for heart failure diagnostics and prognostics boasts a variety of tools and services from numerous reputable providers, all aimed at improving outcomes for heart failure patients. Recent innovations within this space, particularly those leveraging AI and machine learning, signal a trend towards more personalized and precise care approaches.

Regional Insights

In the United States, heart failure is a primary cause of hospitalization among seniors, fueling the demand for advanced therapeutics in a market that highly values innovation. Consumers gravitate towards brands with firm evidence of safety and effectiveness, with recent patents spotlighting innovative formulations and delivery mechanisms. Research is increasingly focused on cutting-edge gene and stem cell therapies, amplified by significant investments in digital health and personalized medicine. Programs such as 'Million Hearts' are crucial in preventing cardiovascular incidents. Canada demonstrates high awareness around heart failure and its risks, supported by a healthcare system that promotes wide treatment access. The market is open to groundbreaking treatments, including home-based monitoring technologies, and leverages investments in regenerative medicine for future solutions. Heart failure therapeutics across Europe benefit from a diverse healthcare landscape, reflecting the region's various systems of healthcare delivery and reimbursement. The aging population and prevalence of heart diseases drive the need for effective treatments, facilitated by initiatives from the European Heart Network aimed at reducing cardiovascular burdens through policies and funding. The Asia-Pacific region is undergoing significant shifts in heart failure treatment demands. China's healthcare sector is evolving rapidly, responding to demographic shifts and lifestyle transformations, bolstered by government healthcare reforms and an uptick in local research and patent filings. Japan's advanced healthcare research, particularly in regenerative medicine, caters to its super-aged society, with consumers showing a preference for local medical innovations. India's growing middle class contributes to an expanding heart failure therapeutics market, further supported by nationwide health initiatives seeking to enhance healthcare services and affordability. In the Middle East and Africa, the heart failure therapeutics landscape varies widely. Affluent Middle Eastern countries like the UAE and Saudi Arabia are seeing an uptick in state-of-the-art treatments powered by enhanced healthcare investments. However, African markets confront access and affordability issues, tackled through efforts by entities like the 'Africa Heart Network' and strategies that encourage local manufacturing and public-private cooperatives.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Heart Failure Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Heart Failure Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Heart Failure Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ABIOMED, Inc., Alembic Pharmaceuticals Limited, Amgen Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter, Inc., Berlin Heart GmbH, Biosensors International Group, Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardiol Therapeutics Inc., Cipla Limited, Dr. Reddy's Laboratories Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Impulse Dynamics, Jarvik Heart, Inc., Johnson & Johnson, LivaNova, PLC, Medtronic PLC, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Orion Corporation, Osypka Medical GmbH, Pfizer, Inc., and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Heart Failure Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Medical Devices
      • Bi-level positive air pressure device
      • Biventricular Pacemaker
      • Continuous Positive Air Pressure Device
      • Heart Pumps
      • Implantable Cardioverter-Defibrillators
      • Implantable Left Ventricular Assist Device
    • Medicines
      • Angiotensin II Receptor Blockers
      • Anticoagulant Medicines
      • Antiplatelet Medicines
      • Blood Pressure Maintaining Agents
      • Diuretics
      • Nitrates
      • Statins
    • Surgery
      • Cardiac Resynchronization
      • Coronary Artery Bypass Grafting
      • Coronary Revascularization
      • Heart Transplant
      • Heart Valve Replacement
  • Type
    • Diagnosis
    • Prognosis
  • Stage
    • Stage A
    • Stage B
    • Stage C
    • Stage D
  • End User
    • Clinic
    • Hospital
    • Medical Research Organization
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Heart Failure Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Heart Failure Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Heart Failure Therapeutics Market?

4. What is the market share of the leading vendors in the Heart Failure Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Heart Failure Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
      • 5.1.1.2. Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
      • 5.1.1.3. Availability and Preferences of Early Diagnosis and Management for Heart Failure
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost and Reimbursement Issues Related to Heart Failure Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations and Development in the Heart Failure Therapeutics
      • 5.1.3.2. Ongoing Government Initiatives and Increasing Investments by Private Sectors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns Related to Management of Heart Failure Condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Extensive consumers shift toward prescribed and personalized medicines for heart health management
    • 5.2.2. Type: Innovations in the diagnostic tools and prognosis helps in better managing the heart health condition
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Heart Failure Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Medical Devices
  • 6.3. Medicines
  • 6.4. Surgery

7. Heart Failure Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Prognosis

8. Heart Failure Therapeutics Market, by Stage

  • 8.1. Introduction
  • 8.2. Stage A
  • 8.3. Stage B
  • 8.4. Stage C
  • 8.5. Stage D

9. Heart Failure Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Clinic
  • 9.3. Hospital
  • 9.4. Medical Research Organization

10. Americas Heart Failure Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Heart Failure Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Heart Failure Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. US FDA approves Medtronic's system for heart condition
    • 13.3.2. J&J drops USD 400 million to acquire new type of stroke-reducing heart implant
    • 13.3.3. FDA Clears MRI Use with Cardiac Contractility Modulation Device

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. HEART FAILURE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEART FAILURE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HEART FAILURE THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BI-LEVEL POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BI-LEVEL POSITIVE AIR PRESSURE DEVICE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BIVENTRICULAR PACEMAKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BIVENTRICULAR PACEMAKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CONTINUOUS POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CONTINUOUS POSITIVE AIR PRESSURE DEVICE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANT MEDICINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANT MEDICINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET MEDICINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET MEDICINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BLOOD PRESSURE MAINTAINING AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BLOOD PRESSURE MAINTAINING AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY NITRATES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY NITRATES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY REVASCULARIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY REVASCULARIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE A, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE A, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE C, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE C, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE D, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE D, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL RESEARCH ORGANIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL RESEARCH ORGANIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 85. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 86. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 92. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 93. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 94. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 95. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 96. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 97. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 98. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 99. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 100. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 101. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 102. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 108. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 109. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 110. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 111. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 112. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 113. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 114. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 115. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 116. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 119. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 125. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 126. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 127. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 128. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 129. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 130. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 133. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 136. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 139. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 140. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 141. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 142. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 143. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 144. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 147. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 150. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 151. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 152. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 153. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 156. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 157. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 158. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 159. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 160. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 161. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 164. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 165. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 166. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 167. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 168. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 185. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 186. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 187. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 188. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 190. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 192. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 196. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 197. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 198. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 199. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 200. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 201. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 202. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 203. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 204. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 205. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 206. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 207. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 210. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 211. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 214. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 215. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 216. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 217. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 218. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 219. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 220. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 221. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 224. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 225. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 230. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 231. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 232. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 233. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 234. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 235. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 238. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 239. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 240. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 241. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 242. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 243. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 244. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 245. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 246. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 247. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 248. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 249. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 252. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 253. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 254. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 255. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 256. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 257. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 258. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 259. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 260. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 261. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 262. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 263. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 266. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 267. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 268. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 269. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 270. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 272. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 273. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 274. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 276. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 277. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 280. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 281. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 282. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 283. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 284. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 285. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 286. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 287. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 288. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 289. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 290. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 291. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 294. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 295. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 296. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 297. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 298. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 299. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 300. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 301. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 302. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 303. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 304. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 305. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 308. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 309. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 310. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 311. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 312. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 313. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 314. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
  • TABLE 315. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
  • TABLE 316. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
  • TABLE 317. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 318. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 319. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
  • TABLE 322. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
  • TABLE 323. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 324. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 325. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 326. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 327. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
  • TABLE 328. THAI